- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Donepezil HCI (drug)
- Drug
- Lead sponsor
- Neurognostics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 15, 2007 · Synced May 21, 2026, 11:24 PM EDT